Masterclass in Clinical Oncology - Autumn edition
25.08.2023 - 10.10.2023
Breast cancer, Clinical cases, Communication skills, Gastro-intestinal tumours, Genito-urinary cancers, Gynaecological cancers, Lung cancer
Deadline for applications: 09 July 2023
Chairs: F. A. Peccatori, IT; S. De Dosso, CH
Host Chairs: F. Grossi, IT; F. Rovera, IT
Aims, objectives and teaching format
The ESO Masterclass is a full immersion, clinical oriented event designed for medical and clinical oncologists with 3-4 years experience in oncology who would like to receive further training on the treatment of tumours from a multidisciplinary point of view. The programme exposes participants to a full spectrum of issues in clinical oncology and to practice-oriented training.
The Masterclass is organized into:
- Plenary lectures on state-of-the-art clinical treatments with reference to clinical guidelines given by renowned international faculty.
- Interactive workshops on communication, social media and managing burnout
- Clinical case presentations/tumour board simulation where each participant presents and discusses a case with an international faculty of top experts in each tumour type.
The Masterclass is divided into two educational parts:
- Pre-recorded online lectures
- In-person event
The online lectures are released before the in-person event to give each participant the opportunity to prepare themselves in their own time and at their own pace.
The in-person event is held in the style of a 3-and-half-day ‘retreat’, giving participants the opportunity to begin building an international oncology network as well as the chance to interact with renowned faculty in an informal environment over a number of days.
This Masterclass is held at the same time at the ESO-EONS Masterclass in Oncology Nursing. Certain educational sessions take place together to give both groups the opportunity to learn in an interdisciplinarity setting.
The Masterclass is held entirely in English and fluency in English is necessary for admission.
The ESO Masterclass in Clinical Oncology: Autumn edition is a closed event for selected participants only.
The Masterclass will be held in English and translation will not be provided.
The Masterclass will take place at UnaHotels in Varese (Milan area), Italy.
A fee of:
- 300 EUR for participant working in High-Middle Income Countries *
- 200 EUR for participants working in Low-Middle income countries *
- Access to the course and its educational resources
- Accommodation for 4 nights at UnaHotels in Varese
- Group transfer from Malpensa airport to the Masterclass venue
- Meals according to the programme
The fee does not cover travel costs, these should be organized and paid by the participant.
A discount of 30 EUR is given to participants who are already ESCO members.
*as defined by the World Bank
Participants will be issued a certificate of attendance (minimum attendance: 75% of the online part + 100% of the in-person event). An online evaluation questionnaire and learning assessment test will need to be completed for both parts in order to get the certificate that will be sent by email.
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE). The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.
ESCO - The ESO College
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enroll in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits.
Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.ESCO.org for more information on how to join ESCO.
Should you have any queries, please do not hesitate to contact the event organisers:
Alice Ciocchini – email@example.com
Dolores Knupfer – firstname.lastname@example.org
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY.
60 PARTICIPANTS WILL BE SELECTED.
Applications deadline: 9th July 2023
IDEAL PROFILE OF THE MASTERCLASS CANDIDATE
- Aged up to 40 years
- 2-3 years’ experience in medical oncology
- Involvement in scientific activities and clinical trials
- Fluency in English
- From ESO’s geographical reach
HOW TO APPLY
Interested oncologists should apply online (at the top of this page) providing:
- Letter describing motivation for attending;
- Supporting letter from head of department or mentor;
- CV with list publications (if the list of publications is not provided, it will be assumed that no articles have been published)
- Clinical case (please, use the provided template below)
- Professional experience form (please, use the provided template below)
CLINICAL CASE PRESENTATION
During the in-person event all participants will have the chance to present a clinical case as a clinical grandround discussion to the faculty and participants. A template giving details of the clinical case you would like to present should be submitted with your application. Please provide a straightforward case found in your daily clinical practice - no uncommon or extremely rare cases. You should include
- Diagnostic considerations
- Results, follow-up
- At least three questions proposed for discussion with the faculty
If you are selected for the Masterclass, you will be asked to prepare a PowerPoint presentation of your case (max 10 slides). If we receive too many cases from one tumour group, we may ask you to change the case topic you submitted during your application. We kindly ask you to let us know your 2nd choice topic if your first choice cannot be accommodated.
Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, Supporting letter, Professional experience template and Clinical Case template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.
Giovanni Damiano Aletti, IEO - European Institute of Oncology, Gyneacological Cancer Dpt., Milano, IT
Anne Arber, University of Surrey, London, UK
Giulia Baciarello, San Camillo-Forlanini Hospitals, Genitourinary Oncology Dpt., Rome, IT
Joerg Beyer, University Hospital of Bern, Oncology and Medicine Dept., Bern, CH
Consuelo Buttigliero, San Luigi Gonzaga Hospital, Genitourinary Dpt., Torino, IT
Felipe A. Calvo Manuel, Clinica Universidad de Navarra, Dept. of Radiation Oncology, Madrid, ES
Fatima Cardoso, Champalimaud Clinical Center, Breast Unit, Lisbon, PT
Maria-João Cardoso, Champalimaud Foundation, Breast Unit, Lisbon, PT
Ian Chau, Royal Marsden Hospital, Department of Medicine, Sutton, Surrey, UK
Ilaria Colombo, Oncology Institute of Southern Switzerland, EOC, Oncology Dpt., Bellinzona, CH
Nicoletta Colombo, Istituto Europeo di Oncologia, Unità di Ginecologia Oncologica, Milano, IT
Carmen Criscitiello, European Institute of Oncology, New Drugs and Early Drug Development for Innovative Therapies Dpt., Milan, IT
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Alessandra Curioni-Fontecedro, Freiburger Spital, HFR Kantonsspital Freiburg, Department of Oncology, Freiburg, CH
Sara De Dosso, Oncology Institute of Southern Switzerland (IOSI), Medical Oncology Dpt., Bellinzona, CH
Johan De Munter, University Hospital Ghent, Oncology Dpt., Ghent, BE
Sarah Derks, Gastro-intestinal Tumours Dpt., Amsterdam UMC, Amsterdam, NL
Andre D'Hoore, UZ Gasthuisberg, Dept. of Surgery, Leuven, BE
Rodrigo Dienstmann, Vall d’Hebron Institute of Oncology, Molecular Therapeutic Research Unit, Barcelona, ES
Andreas Dietz, University Hospital Leipzig, ENT Dpt., Leipzig, DE
Alexandru Eniu, Riviera-Chablais Hospital, Interdisciplinary Oncology Service, Rennaz, CH
Lesley Fallowfield, SHORE-C, Brighton & Sussex Medical School, Brighton, UK
Pierfrancesco Franco, University of Eastern Piedmont, Dept. of Translational Medicine, Novara, IT
Martin Früh, St. Gallen Cantonal Hospital, Dept. of Internal Medicine, St. Gallen, CH
Andrea Gallina, EOC - Ente Ospedaliero Cantonale, Urology Dpt., Bellinzona, CH
Marina Garassino, University of Chicago Medicine & Biological Sciences, Section of Hematology | Oncology, Chicago, US
Fady B. Geara, Cleveland Clinic Abu Dhabi, Dept. of Radiation Oncology, Abu Dhabi, AE
Alessandra Gennari, Università Piemonte Orientale, Translational Medicine Dpt., Novara, IT
Francesco Grossi, Medical Oncology Dpt., Università degli Studi dell’Insubria, Varese, IT
Federica Grosso, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo, ., Alessandria, IT
Andrew Hoy, Independent Palliative Medicine Practice, Epsom, UK
Andrea Imperatori, University of Insubria, Lung Cancer Dpt., Varese, IT
Orit Kaidar-Person, Sheba Medical Center, Breast Radiation Unit, Ramat Gan, IL
Izidor Kern, University Clinic Golnik, Dept. of Pathology, Golnik, SI
Stephanie Kroeze, University Hospital Zurich, Radio-Oncology Dept., Zurich, CH
Matteo Lambertini, University of Genova - San Martino Hospital, Genoa, IT
Pauline Leonard, National Health Service, Oncology and Communication Dpt., London, UK
Michelle Lockley, Queen Mary University of London, Gyneacological Cancers Dpt., London, UK
Gilberto Morgan, Skane University Hospital, Limhamn, SE
Andrea Necchi, IRCCS San Raffaele Hospital, Genitourinary Medical Oncology Division, Milan, IT
Christoph Oing, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
Olivia Pagani, Riviera-Chablais Hospital, Interdisciplinary Oncology Service, Rennaz, CH
Petra Pandur, Ulm University, Oncology Dpt., Ulm, DE
Demetris Papamichael, Bank of Cyprus Oncology Centre, Medical Oncology Dpt., Nicosia, CY
Fedro Alessandro Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
Giancarlo Pruneri, National Cancer Institute, IRCCS Foundation, Pathology Dpt., Milano, IT
Amanda Psyrri, Attikon University Hospital, Medical Oncology Dept., Chaidari, GR
Isabelle Ray-Coquard, Léon Bérard Center, Dept. of Medical Oncology, Lyon, FR
Christian Rolfo, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Center for Thoracic Oncology, New York, US
Riccardo Rosati, San Raffaele Hospital, Surgery Dpt., Milano, IT
Francesca Angela Rovera, University of Insubria, Dept. of Surgical Sciences, Varese, IT
Laura Rubbia-Brandt, Hôpitaux Universitaires Genève, Pathology Dept., Geneve, CH
Manuela Schmidinger, Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, AT
Uta Schmidt-Strassburger, Ulm University, Learning and Teaching, Medical Faculty, Ulm, DE
Isabelle Schmitt-Opitz, University of Zurich Hospital, Dept. of Thoracic Surgery, Zurich, CH
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Thomas Seufferlein, Ulm University Hospital, Dept. of Internal Medicine I, Ulm, DE
Pelagia Tsoutsou, Hôpitaux Universitaires de Genève (HUG), Radiation Oncology Dpt., Geneve, CH
Eric Van Cutsem, University Hospital Leuven, Digestive Oncology Dept., Leuven, BE
Ursula Vogl, Cantonal Hospital of Southern Switzerland (EOC), IOSI - Oncology Institute of Southern Switzerland, Bellinzona, CH
Ignacio Zapardiel, La Paz University Hospital, Gynecologic Oncology Unit, Madrid, ES